Proud to announce the publication of our recent study, “Transcutaneous Vagus Nerve Stimulation is Associated with Lower Mechanical Ventilation and Mortality in COVID-19 Patients“.
Conducted in Buenos Aires, the study demonstrated that using transcutaneous vagus nerve stimulation (taVNS) used 4 times daily in hospitalized patients with COVID-19 was associated with a low requirement for mechanical ventilation and low mortality compared to other hospitalization cohorts.
Transcutaneous vagus nerve stimulation is a potent inhibitor of inflammatory cytokines. Ideal for any hospital setting, taVNS is low cost, safe and a single device can be used among different patients simultaneously. #covid #vns #vagusnerve #NemechekTechnologies